Kendall Law Group Investigates Micrus Endovascular Corp. Acquisition for Shareholders

Kendall Law Group, a national securities firm led by a former federal judge Joe Kendall, is investigating Micrus Endovascular Corp. (NASDAQ:MEND) for shareholders in connection with the proposed acquisition by Johnson & Johnson. The national securities firm’s investigation seeks to determine whether Micrus and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are a Micrus shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at skendall@kendalllawgroup.com.

On July 12, 2010, the companies announced that they had entered into an agreement for Micrus to be acquired by Johnson & Johnson in a transaction valued at approximately $480 million. The offer price represents a 5.5% premium for Micrus based on Friday's $22.19 closing share price. On June 8, 2010, Micrus reported annual increases of $12.89 million in total revenue and $22.58 in net income over the prior year. In addition, according to Thompson/First Call, at least one analyst has set a price target of $25 per share.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.

Micrus Endovascular (MM) (NASDAQ:MEND)
過去株価チャート
から 10 2024 まで 11 2024